Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease

被引:118
|
作者
Di Minno, Matteo Nicola Dario [1 ]
Russolillo, Anna [1 ]
Lupoli, Roberta [1 ]
Ambrosino, Pasquale [1 ]
Di Minno, Alessandro [1 ]
Tarantino, Giovanni [1 ]
机构
[1] Univ Naples Federico II, Dept Clin & Expt Med, Reg Reference Ctr Coagulat Disorders, I-80131 Naples, Italy
关键词
Hepatic steatosis; Non-alcoholic fatty liver disease; Omega-3 polyunsaturated fatty acids; Animal models; ACTIVATED-RECEPTOR-ALPHA; ELEMENT-BINDING PROTEIN-1; AMELIORATE HEPATIC STEATOSIS; OXIDATIVE STRESS; INSULIN-RESISTANCE; GENE-EXPRESSION; ACID REGULATION; MURINE MODEL; MOLECULAR-MECHANISMS; METABOLIC SYNDROME;
D O I
10.3748/wjg.v18.i41.5839
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) has been recognized as a major health burden. It is the most important cause of chronic liver disease and a major independent cardiovascular risk factor. Lacking a definite treatment for NAFLD, a specific diet and an increase in physical activity represent the most commonly used therapeutic approaches. In this review, major literature data about the use of omega-3 polyunsaturated fatty acids (n-3 PUFAs) as a potential treatment of NAFLD have been described. n-3 PUFAs, besides having a beneficial impact on most of the cardio-metabolic risk factors (hypertension, hyperlipidemia, endothelial dysfunction and atherosclerosis) by regulating gene transcription factors [i.e., peroxisome proliferator-activated receptor (PPAR) alpha, PPAR gamma, sterol regulatory element-binding protein-1, carbohydrate responsive element-binding protein], impacts both lipid metabolism and on insulin sensitivity. In addition to an enhancement of hepatic beta oxidation and a decrease of the endogenous lipid production, n-3 PUFAs are able to determine a significant reduction of the expression of pro-inflammatory molecules (tumor necrosis factor-alpha and interleukin-6) and of oxygen reactive species. Further strengthening the results of the in vitro studies, both animal models and human intervention trials, showed a beneficial effect of n-3 PUFAs on the severity of NAFLD as expressed by laboratory parameters and imaging measurements. Despite available results provided encouraging data about the efficacy of n-3 PUFAs as a treatment of NAFLD in humans, well-designed randomized controlled trials of adequate size and duration, with histological endpoints, are needed to assess the long-term safety and efficacy of PUFA, as well as other therapies, for the treatment of NAFLD and non-alcoholic steatohepatitis patients. It is worthwhile to consider that n-3 PUFAs cannot be synthesized by the human body and must be derived from exogenous sources (fish oil, flaxseeds, olive oil) which are typical foods of the Mediterranean diet, known for its beneficial effects in preventing obesity, diabetes and, in turn, cardiovascular events. According to these data, it is important to consider that most of the beneficial effects of n-3 PUFAs can also be obtained by an equilibrate nutrition program. (C) 2012 Baishideng. All rights reserved.
引用
收藏
页码:5839 / 5847
页数:9
相关论文
共 50 条
  • [41] Surgical Treatment of Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease
    Weiner, R. A.
    [J]. DIGESTIVE DISEASES, 2010, 28 (01) : 274 - 279
  • [42] Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
    Francque, Sven
    Vonghia, Luisa
    [J]. ADVANCES IN THERAPY, 2019, 36 (05) : 1052 - 1074
  • [43] Current treatment of non-alcoholic fatty liver disease
    Ahmed, Mohamed H.
    Byrne, Christopher D.
    [J]. DIABETES OBESITY & METABOLISM, 2009, 11 (03): : 188 - 195
  • [44] Treatment regimens for non-alcoholic fatty liver disease
    Lam, Brian P.
    Younossi, Zobair M.
    [J]. ANNALS OF HEPATOLOGY, 2009, 8 : S51 - S59
  • [45] The diagnosis and treatment of non-alcoholic fatty liver disease
    Altinbas, A.
    Sowa, J. -P.
    Hasenberg, T.
    Canbay, A.
    [J]. MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2015, 61 (03) : 159 - 169
  • [46] Metformin in the treatment of non-alcoholic fatty liver disease
    De Lusong, M. A.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S192 - S192
  • [47] Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
    Sven Francque
    Luisa Vonghia
    [J]. Advances in Therapy, 2019, 36 : 1052 - 1074
  • [48] Rosiglitazone treatment in non-alcoholic fatty liver disease
    Szymanska-Garbacz, E.
    Saryusz-Wolska, M.
    Jablkowski, M.
    Bialkowska, J.
    Borkowska, A.
    Omulecka, A.
    Loba, J.
    Czupryniak, L.
    [J]. DIABETOLOGIA, 2008, 51 : S368 - S368
  • [49] Current treatment for non-alcoholic fatty liver disease
    Moctezuma-Velazquez, C.
    [J]. REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2018, 83 (02): : 125 - 133
  • [50] Current treatment of non-alcoholic fatty liver disease
    Paternostro, Rafael
    Trauner, Michael
    [J]. JOURNAL OF INTERNAL MEDICINE, 2022, 292 (02) : 190 - 204